IRIS
DI GIACOMO, ANNA MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.250
EU - Europa 3.837
AS - Asia 683
OC - Oceania 9
AF - Africa 8
SA - Sud America 4
Totale 8.791
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.237
IE - Irlanda 1.025
IT - Italia 814
GB - Regno Unito 538
RU - Federazione Russa 485
CN - Cina 306
SE - Svezia 265
SG - Singapore 207
FR - Francia 195
DE - Germania 178
UA - Ucraina 170
VN - Vietnam 102
FI - Finlandia 63
ES - Italia 59
IN - India 16
NL - Olanda 12
CA - Canada 10
AU - Australia 8
KR - Corea 8
BE - Belgio 7
TR - Turchia 6
CH - Svizzera 4
HK - Hong Kong 4
PL - Polonia 4
SA - Arabia Saudita 4
AZ - Azerbaigian 3
CI - Costa d'Avorio 3
IR - Iran 3
PH - Filippine 3
PK - Pakistan 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
BO - Bolivia 2
EE - Estonia 2
GR - Grecia 2
HR - Croazia 2
ID - Indonesia 2
KG - Kirghizistan 2
MY - Malesia 2
NO - Norvegia 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
UZ - Uzbekistan 2
AT - Austria 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
EG - Egitto 1
IQ - Iraq 1
JP - Giappone 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LT - Lituania 1
MA - Marocco 1
MX - Messico 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
Totale 8.791
Salva come PNG Salva come JPEG
Città #
Dublin 1.021
Fairfield 817
Southend 453
Woodbridge 399
Ashburn 380
Seattle 330
Houston 301
Cambridge 299
Wilmington 289
Siena 262
Princeton 170
Jacksonville 157
Singapore 156
Ann Arbor 134
Chandler 120
Dong Ket 101
San Mateo 84
Beijing 82
Shanghai 73
Dearborn 65
Moscow 60
Málaga 57
Florence 56
New York 51
Helsinki 49
Rome 47
San Diego 47
Milan 41
London 25
Nanjing 25
Bologna 18
Santa Clara 18
Fremont 16
San Francisco 13
Boardman 12
Empoli 12
Redwood City 12
Sesto Fiorentino 11
Nanchang 10
Norwalk 10
Hefei 9
Montevarchi 9
Delhi 8
Guangzhou 8
Kilburn 8
Padova 8
Palermo 8
Asciano 7
Brussels 7
Cascina 7
Kunming 7
Lambeth 7
Lappeenranta 7
Lucca 7
Toronto 7
Venezia 7
Amsterdam 6
Marano Vicentino 6
Tianjin 6
Yongsan-gu 6
Catania 5
Hounslow 5
Islington 5
Novara 5
Phoenix 5
Trieste 5
Acton 4
Bari 4
Changsha 4
Chiswick 4
Columbus 4
Düsseldorf 4
Hong Kong 4
Jinan 4
Labico 4
Livorno 4
Naples 4
Pistoia 4
Riyadh 4
Shenyang 4
Washington 4
Abidjan 3
Ascoli Piceno 3
Baku 3
Carmignano 3
Ferentino 3
Hangzhou 3
Karlsruhe 3
Lavis 3
Palo del Colle 3
Prunetta 3
Schwielowsee 3
Stockholm 3
Sydney 3
Abu Dhabi 2
Altamura 2
Arezzo 2
Arlington 2
Athens 2
Bergamo 2
Totale 6.569
Salva come PNG Salva come JPEG
Nome #
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 218
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study 213
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 181
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 174
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy 174
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab 173
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy 158
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 149
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. 139
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 130
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 129
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 126
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 117
Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/ mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study 114
“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 112
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients 106
The italian experience on the feasibility and safety of ipilmumab therapy in pretracted metastatic melanoma patients 106
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 104
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications 103
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients 103
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models 103
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis 101
Predictors of responses to immune checkpoint blockade in advanced melanoma 100
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 99
Immunotherapy targeting immune check-point(s) in brain metastases 98
Molecular pathways: At the crossroads of cancer epigenetics and immunotherapy 98
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab 96
null 95
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy 93
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study 91
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: Comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells 89
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 87
Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond 87
null 87
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients 86
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications 83
A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial 82
Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients 81
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 81
The Italian experience on the feasibility and safety of ipilimumab therapy in pretreated metastatic melanoma patients 80
Epigenetics meets immune checkpoints 80
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients 77
null 75
Ipilmumab in pretreated metastatic uveal melanoma patiens; safety and clinical efficacy 74
Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? 73
Challenges in lung cancer therapy during the COVID-19 pandemic 73
Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial 73
Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial 73
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy 73
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients 72
Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications 71
Epigenetic immune remodeling of mesothelioma cells: A new strategy to improve the efficacy of immunotherapy 71
Long-term follow-up of a papillary tumor of the pineal region: addendum to a case report 70
Nivolumab plus ipilimumab in melanoma brain metastases 70
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 69
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role? 67
Back to simplicity: A four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients 67
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab 65
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study 64
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications 62
Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID 61
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features 61
Can epigenetics have a clinical impact in the treatment of melanoma? 61
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial 61
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial 61
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 61
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 60
Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial 58
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study 58
null 58
Dietary compounds and cutaneous malignant melanoma: Recent advances from a biological perspective 58
The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases 56
null 56
Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy 55
SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: Clinical course and outcome 55
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 54
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma 54
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma 54
The cost of unresectable stage III or stage IV melanoma in Italy 53
The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors 53
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma 53
Update on the role of ipilimumab in melanoma and first data on new combination therapies 52
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial 52
Long term survival and immunological correlates in metastatic melanoma treated with IPILIMUMAB 10 mgs within an expanded access program 51
A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: A case report 51
A novel microRNA signature for the detection of melanoma by liquid biopsy 50
Effects of molecular heterogeneity on survival of patients with BRAFV600-mutated melanoma treated with vemurafenib with or without cobimetinib in the coBRIM study 49
Epigenetic immunomodulation of hematopoietic malignancies 48
null 47
Health-related quality of life in patients with fully resected BRAFV600 mutation–positive melanoma receiving adjuvant vemurafenib 47
Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix 47
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma 46
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma 45
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy 43
Primary analysis and 4-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases 40
Germline and somatic mutations in patients with multiple primary melanomas: A next generation sequencing study 39
Immunotherapy of brain metastases: breaking a "dogma" 38
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial 37
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria 37
Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness 37
Totale 8.122
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.202
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.202
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.745 0 0 0 0 252 193 355 327 234 196 59 129
2020/20212.017 48 173 100 115 427 251 71 309 80 165 59 219
2021/2022989 43 87 91 20 18 65 34 42 74 137 123 255
2022/20231.378 112 90 223 118 58 246 44 71 96 60 220 40
2023/20241.738 67 66 161 63 49 413 581 62 44 27 42 163
2024/2025897 127 153 333 244 40 0 0 0 0 0 0 0
Totale 9.314